Biosafety of Recombinant Adeno-associated Virus Vectors

Current Gene Therapy

Volumn 13, Issue 6, 2013, Pages 434-452

  Dismuke, David J ^a,b   Tenenbaum, Liliane ^c   Samulski, R Jude ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Adeno associated virus; Biosafety; Capsid modification; Clinical trials; Gene delivery; Immune response; Insertional mutagenesis; Targeting

Indexed keywords

DNA FRAGMENT; PARVOVIRUS VECTOR; PROTEIN P53; THYMIDINE KINASE;

ADENOVIRUS INFECTION; ALPHA ANTITRYPSIN DEFICIENCY; ARTICLE; BIOSAFETY; CANCER GENE THERAPY; CLINICAL EVALUATION; CYSTIC FIBROSIS; DNA REPLICATION; EXPRESSION VECTOR; EYE DISEASE; GENE DELETION; GENE EXPRESSION REGULATION; GENE TARGETING; GENOME ANALYSIS; HEMOPHILIA B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MUSCLE DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SOMATIC GENE THERAPY; STORAGE DISEASE; TRANSCRIPTION REGULATION; TRANSGENE; VACCINATION; VIRUS GENOME; VIRUS INACTIVATION; VIRUS REPLICATION;

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DEPENDOVIRUS; DNA, RECOMBINANT; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HAZARDOUS SUBSTANCES; HUMANS;

EID: 84891803470     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/15665232113136660007     Document Type: Article

References (283)

1. Terheggen HG, Lowenthal A, Lavinha F, Colombo JP, Rogers S. Unsuccessful trial of gene replacement in arginase deficiency. Z Kinderheilkd 1975; 119(1):1-3.
2. Wade N. Gene therapy caught in more entanglements. Science 1981; 212(4490):24-5.
3. Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999; 401(6753):517-8.
4. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118(9):3132-42.
5. Wirth T, Parker N, Yla-Herttuala S. History of gene therapy. Gene 2013; 525(2):162-9.
6. Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Ther 1995; 2(6):357-62.
7. Daya S, Berns KI. Gene Therapy Using Adeno-Associated Virus Vectors. Clin Microbiol Rev 2008; 21(4):583-93.
8. McCarty DM, Ryan JH, Zolotukhin S, Zhou X, Muzyczka N. Interaction of the adeno-associated virus Rep protein with a sequence within the A palindrome of the viral terminal repeat. J Virol 1994; 68(8):4998-5006.
9. Brister JR, Muzyczka N. Mechanism of Rep-mediated adenoassociated virus origin nicking. J Virol 2000 Sep;74(17):7762-71.
10. Nash K, Chen W, Salganik M, Muzyczka N. Identification of Cellular Proteins That Interact with the Adeno-Associated Virus Rep Protein. J Virol 2009; 83(1):454-69.
11. Stahnke S, Lux K, Uhrig S, et al. Intrinsic phospholipase A2 activity of adeno-associated virus is involved in endosomal escape of incoming particles. Virology 2011; 409(1):77-83.
12. Girod A, Wobus CE, Zadori Z, et al. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol 2002; 83(Pt 5):973-8.
13. Warrington KH Jr, Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S, Muzyczka N. Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol 2004; 78(12):6595-609.
14. Lerch TF, O'Donnell JK, Meyer NL, et al. Structure of AAV-DJ, a retargeted gene therapy vector: cryo-electron microscopy at 4.5 A resolution. Structure 2012; 20(8):1310-20.
15. Lerch TF, Xie Q, Chapman MS. The structure of adeno-associated virus serotype 3B (AAV-3B): insights into receptor binding and immune evasion. Virology 2010; 403(1):26-36.
16. Xie Q, Bu W, Bhatia S, et al. The atomic structure of adenoassociated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A 2002; 99(16):10405-10.
17. Xie Q, Ongley HM, Hare J, Chapman MS. Crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 6. Acta Crystallogr Sect F Struct Biol Cryst Commun 2008; 64(Pt 11):1074-8.
18. Govindasamy L, Dimattia MA, Gurda BL, et al. Structural insights into adeno-associated virus serotype 5. J Virol 2013; 87(20):11187-99.
19. Govindasamy L, Padron E, McKenna R, et al. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J Virol 2006; 80(23):11556-70.
20. DiMattia MA, Nam HJ, Van Vliet K, et al. Structural insight into the unique properties of adeno-associated virus serotype 9. J Virol 2012 Jun;86(12):6947-6958.
21. Xie Q, Hare J, Turnigan J, Chapman MS. Large-scale production, purification and crystallization of wild-type adeno-associated virus-2. J Virol Methods 2004; 122(1):17-27.
22. Nam HJ, Lane MD, Padron E, et al. Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol 2007; 81(22):12260-71.
23. Ng R, Govindasamy L, Gurda BL, et al. Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J Virol 2010; 84(24):12945-57.
24. Padron E, Bowman V, Kaludov N, et al. Structure of adenoassociated virus type 4. J Virol 2005; 79(8):5047-58.
25. Walters RW, Agbandje-McKenna M, Bowman VD, et al. Structure of adeno-associated virus serotype 5. J Virol 2004; 78(7):3361-71.
26. Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 2012; 20(4):699-708.
27. Parrish CR. Structures and functions of parvovirus capsids and the process of cell infection. Curr Top Microbiol Immunol 2010; 343:149-76.
28. Bleker S, Pawlita M, Kleinschmidt JA. Impact of capsid conformation and Rep-capsid interactions on adeno-associated virus type 2 genome packaging. J Virol 2006; 80(2):810-20.
29. Horowitz ED, Finn MG, Asokan A. Tyrosine cross-linking reveals interfacial dynamics in adeno-associated viral capsids during infection. ACS Chem Biol 2012; 7(6):1059-66.
30. Horowitz ED, Rahman KS, Bower BD, et al. Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release. J Virol 2013; 87(6):2994-3002.
31. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72(2):1438-45.
32. Wu Z, Miller E, Agbandje-McKenna M, Samulski RJ. Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol 2006; 80(18):9093-103.
33. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 2001; 75(15):6884-93.
34. Walters RW, Yi SM, Keshavjee S, Brown KE, Welsh MJ, Chiorini JA, et al. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 2001; 276(23):20610-6.
35. Shen S, Horowitz ED, Troupes AN, et al. Engraftment of a galactose receptor footprint onto adeno-associated viral capsids im proves transduction efficiency. J Biol Chem 2013; 288(40):28814-23.
36. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 1999; 5(1):71-7.
37. Di Pasquale G, Davidson BL, Stein CS, et al. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 2003; 9(10):1306-12.
38. Akache B, Grimm D, Shen X, et al. A two-hybrid screen identifies cathepsins B and L as uncoating factors for adeno-associated virus 2 and 8. Mol Ther 2007; 15(2):330-9.
39. Grieger JC, Snowdy S, Samulski RJ. Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly. J Virol 2006; 80(11):5199-210.
40. Johnson JS, Li C, DiPrimio N, Weinberg MS, McCown TJ, Samulski RJ. Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J Virol 2010; 84(17):8888-902.
41. Popa-Wagner R, Porwal M, Kann M, et al. Impact of VP1-specific protein sequence motifs on adeno-associated virus type 2 intracellular trafficking and nuclear entry. J Virol 2012; 86(17):9163-74.
42. Nonnenmacher M, Weber T. Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther 2012; 19(6):649-58.
43. Xiao PJ, Samulski RJ. Cytoplasmic trafficking, endosomal escape, and perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by microtubule network. J Virol 2012; 86(19):10462-73.
44. Popa-Wagner R, Sonntag F, Schmidt K, King J, Kleinschmidt JA. Nuclear translocation of adeno-associated virus type 2 capsid proteins for virion assembly. J Gen Virol 2012; 93(Pt 9):1887-98.
45. Young S.M. Jr., McCarty DM, Degtyareva N, Samulski RJ. Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombination. J Virol 2000; 74(9):3953-66.
46. Sonntag F, Kother K, Schmidt K, et al. The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes. J Virol 2011; 85(23):12686-97.
47. Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci U S A 2010; 107(22):10220-5.
48. Kapranov P, Chen L, Dederich D, et al. Native molecular state of adeno-associated viral vectors revealed by single-molecule sequencing. Hum Gene Ther 2012; 23(1):46-55.
49. Maguire CA, Balaj L, Sivaraman S, et al. Microvesicle-associated AAV vector as a novel gene delivery system. Mol Ther 2012; 20(5):960-71.
50. Atchison RW, Casto BC, Hammon WM. Adenovirus-Associated Defective Virus Particles. Science 1965; 149(3685):754-6.
51. Georg-Fries B, Biederlack S, Wolf J, zur Hausen H. Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology 1984; 134(1):64-71.
52. Schlehofer JR, Ehrbar M, zur Hausen H. Vaccinia virus, herpes simplex virus, and carcinogens induce DNA amplification in a human cell line and support replication of a helpervirus dependent parvovirus. Virology 1986; 152(1):110-7.
53. Walz C, Deprez A, Dupressoir T, Durst M, Rabreau M, Schlehofer JR. Interaction of human papillomavirus type 16 and adenoassociated virus type 2 co-infecting human cervical epithelium. J Gen Virol 1997; 78 (Pt 6):1441-52.
54. Yalkinoglu AO, Heilbronn R, Burkle A, Schlehofer JR, zur Hausen H. DNA amplification of adeno-associated virus as a response to cellular genotoxic stress. Cancer Res 1988; 48(11):3123-29.
55. Yakobson B, Koch T, Winocour E. Replication of adeno-associated virus in synchronized cells without the addition of a helper virus. J Virol 1987; 61(4):972-81.
56. Russell DW, Alexander IE, Miller AD. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci U S A 1995; 92(12):5719-23.
57. Meyers C, Mane M, Kokorina N, Alam S, Hermonat PL. Ubiquitous human adeno-associated virus type 2 autonomously replicates in differentiating keratinocytes of a normal skin model. Virology 2000; 272(2):338-46.
58. Casto BC, Atchison RW, Hammon WM. Studies on the relationship between adeno-associated virus type I (AAV-1) and adenoviruses. I. Replication of AAV-1 in certain cell cultures and its effect on helper adenovirus. Virology 1967; 32(1):52-9.
59. Antoni BA, Rabson AB, Miller IL, Trempe JP, Chejanovsky N, Carter BJ. Adeno-associated virus Rep protein inhibits human immunodeficiency virus type 1 production in human cells. J Virol 1991; 65(1):396-404.
60. Buller RM, Janik JE, Sebring ED, Rose JA. Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus replication. J Virol 1981; 40(1):241-7.
61. Meyers C, Alam S, Mane M, Hermonat PL. Altered biology of adeno-associated virus type 2 and human papillomavirus during dual infection of natural host tissue. Virology 2001; 287(1):30-9.
62. Chang LS, Shi Y, Shenk T. Adeno-associated virus P5 promoter contains an adenovirus E1A-inducible element and a binding site for the major late transcription factor. J Virol 1989; 63(8):3479-88.
63. Richardson WD, Westphal H. A cascade of adenovirus early functions is required for expression of adeno-associated virus. Cell 1981; 27(Pt 2):133-41.
64. Laughlin CA, Jones N, Carter BJ. Effect of deletions in adenovirus early region 1 genes upon replication of adeno-associated virus. J Virol 1982; 41(3):868-76.
65. Samulski RJ, Shenk T. Adenovirus E1B 55-Mr polypeptide facilitates timely cytoplasmic accumulation of adeno-associated virus mRNAs. J Virol 1988; 62(1):206-10.
66. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, Wilson JM. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996; 70(1):520-32.
67. Carter BJ, Antoni BA, Klessig DF. Adenovirus containing a deletion of the early region 2A gene allows growth of adeno-associated virus with decreased efficiency. Virology 1992; 191(1):473-6.
68. Chang LS, Shenk T. The adenovirus DNA-binding protein stimulates the rate of transcription directed by adenovirus and adenoassociated virus promoters. J Virol 1990; 64(5):2103-9.
69. Janik JE, Huston MM, Cho K, Rose JA. Efficient synthesis of adeno-associated virus structural proteins requires both adenovirus DNA binding protein and VA I RNA. Virology 1989; 168(2):320-9.
70. Nayak R, Pintel DJ. Adeno-associated viruses can induce phosphorylation of eIF2alpha via PKR activation, which can be overcome by helper adenovirus type 5 virus-associated RNA. J Virol 2007; 81(21):11908-16.
71. Atchison RW, Casto BC, Hammon WM. Adenovirus-Associated Defective Virus Particles. Science 1965; 149(3685):754-6.
72. Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci U S A 1966; 55(6):1467-74.
73. Blacklow NR, Hoggan MD, Rowe WP. Isolation of adenovirusassociated viruses from man. Proc Natl Acad Sci U S A 1967; 58(4):1410-5.
74. Blacklow NR, Hoggan MD, Rowe WP. Serologic evidence for human infection with adenovirus-associated viruses. J Natl Cancer Inst 1968; 40(2):319-27.
75. Blacklow NR, Hoggan MD, Kapikian AZ, Austin JB, Rowe WP. Epidemiology of adenovirus-associated virus infection in a nursery population. Am J Epidemiol 1968; 88(3):368-78.
76. Blacklow NR, Hoggan MD, Sereno MS, et al. A seroepidemiologic study of adenovirus-associated virus infection in infants and children. Am J Epidemiol 1971; 94(4):359-66.
77. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol 1999; 59(3):406-11.
78. Luchsinger E, Strobbe R, Wellemans G, Dekegel D, Sprecher-Goldberger S. Haemagglutinating adeno-associated virus (AAV) in association with bovine adenovirus type 1. Brief report. Arch Gesamte Virusforsch 1970; 31(3):390-2.
79. Blacklow NR, Hoggan MD, Rowe WP. Immunofluorescent studies of the potentiation of an adenovirus-associated virus by adenovirus 7. J Exp Med 1967; 125(5):755-65.
80. Blacklow NR. Potentiation of an adenovirus-associated virus by herpes simplex virus type-2-transformed cells. J Natl Cancer Inst 1975; 54(1):241-4.
81. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009; 199(3):381-90.
82. Cheung AK, Hoggan MD, Hauswirth WW, Berns KI. Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells. J Virol 1980; 33(2):739-48.
83. Kotin RM, Berns KI. Organization of adeno-associated virus DNA in latently infected Detroit 6 cells. Virology 1989; 170(2):460-7.
84. Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A 1990; 87(6):2211-5.
85. Samulski RJ, Zhu X, Xiao X, et al. Targeted integration of adenoassociated virus (AAV) into human chromosome 19. EMBO J 1991; 10(12):3941-50.
86. Ogata T, Kozuka T, Kanda T. Identification of an insulator in AAVS1, a preferred region for integration of adeno-associated virus DNA. J Virol 2003; 77(16):9000-7.
87. Dutheil N, Shi F, Dupressoir T, Linden RM. Adeno-associated virus site-specifically integrates into a muscle-specific DNA region. Proc Natl Acad Sci U S A 2000; 97(9):4862-6.
88. Henckaerts E, Dutheil N, Zeltner N, et al. Site-specific integration of adeno-associated virus involves partial duplication of the target locus. Proc Natl Acad Sci U S A 2009; 106(18):7571-6.
89. Lombardo A, Cesana D, Genovese P, et al. Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat Methods 2011; 8(10):861-9.
90. Zhu H, Lau CH, Goh SL, Liang Q, Chen C, Du S, et al. Baculoviral transduction facilitates TALEN-mediated targeted transgene integration and Cre/LoxP cassette exchange in human-induced pluripotent stem cells. Nucleic Acids Res 2013; 41(19):e180. doi: 10.1093/nar/gkt721.
91. Ward P, Walsh CE. Targeted integration of a rAAV vector into the AAVS1 region. Virology 2012; 433(2):356-66.
92. Schnepp BC, Jensen RL, Chen CL, Johnson PR, Clark KR. Characterization of adeno-associated virus genomes isolated from human tissues. J Virol 2005; 79(23):14793-803.
93. Huser D, Gogol-Doring A, Lutter T, et al. Integration preferences of wildtype AAV-2 for consensus rep-binding sites at numerous loci in the human genome. PLoS Pathog 2010; 6(7):e1000985.
94. Hernandez YJ, Wang J, Kearns WG, Loiler S, Poirier A, Flotte TR. Latent adeno-associated virus infection elicits humoral but not cellmediated immune responses in a nonhuman primate model. J Virol 1999; 73(10):8549-58.
95. Zacharias J, Romanova LG, Menk J, Philpott NJ. P53 Inhibits Adeno-Associated Viral Vector Integration. Hum Gene Ther 2011; 22(11):1445-51.
96. Batchu RB, Shammas MA, Wang JY, Munshi NC. Interaction of adeno-associated virus Rep78 with p53: implications in growth inhibition. Cancer Res 1999; 59(15):3592-5.
97. Saudan P, Vlach J, Beard P. Inhibition of S-phase progression by adeno-associated virus Rep78 protein is mediated by hypophosphorylated pRb. Embo J 2000; 19(16):4351-61.
98. Berthet C, Raj K, Saudan P, Beard P. How adeno-associated virus Rep78 protein arrests cells completely in S phase. Proc Natl Acad Sci U S A 2005; 102(38):13634-9.
99. Schmidt M, Afione S, Kotin RM. Adeno-associated virus type 2 Rep78 induces apoptosis through caspase activation independently of p53. J Virol 2000; 74(20):9441-50.
100. Alam S, Bowser BS, Conway MJ, Israr M, Tandon A, Meyers C. Adeno-associated virus type 2 infection activates caspase dependent and independent apoptosis in multiple breast cancer lines but not in normal mammary epithelial cells. Mol Cancer 2011; 10:97-4598-10-97.
101. Raj K, Ogston P, Beard P. Virus-mediated killing of cells that lack p53 activity. Nature 2001; 412(6850):914-7.
102. Jurvansuu J, Fragkos M, Ingemarsdotter C, Beard P. Chk1 instability is coupled to mitotic cell death of p53-deficient cells in response to virus-induced DNA damage signaling. J Mol Biol 2007; 372(2):397-406.
103. Fragkos M, Breuleux M, Clement N, Beard P. Recombinant adenoassociated viral vectors are deficient in provoking a DNA damage response. J Virol 2008; 82(15):7379-87.
104. Schwartz RA, Carson CT, Schuberth C, Weitzman MD. Adenoassociated virus replication induces a DNA damage response coordinated by DNA-dependent protein kinase. J Virol 2009; 83(12):6269-78.
105. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72(3):2224-32.
106. Grieger JC, Choi VW, Samulski RJ. Production and characterization of adeno-associated viral vectors. Nat Protoc 2006; 1(3):1412-28.
107. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 2002; 99(18):11854-9.
108. Gao G, Vandenberghe LH, Alvira MR, et al. Clades of Adenoassociated viruses are widely disseminated in human tissues. J Virol 2004; 78(12):6381-8.
109. Bantel-Schaal U, zur Hausen H. Characterization of the DNA of a defective human parvovirus isolated from a genital site. Virology 1984; 134(1):52-63.
110. Rutledge EA, Halbert CL, Russell DW. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol 1998; 72(1):309-19.
111. Rabinowitz JE, Bowles DE, Faust SM, Ledford JG, Cunningham SE, Samulski RJ. Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J Virol 2004; 78(9):4421-32.
112. Rabinowitz JE, Rolling F, Li C, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76(2):791-801.
113. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008; 16(6):1073-80.
114. Alisky JM, Hughes SM, Sauter SL, et al. Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors. Neuroreport 2000; 11(12):2669-73.
115. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003; 10(26):2112-8.
116. McCarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther 2008; 16(10):1648-56.
117. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001; 8(16):1248-54.
118. Fu H, Muenzer J, Samulski RJ, et al. Self-complementary adenoassociated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol Ther 2003; 8(6):911-7.
119. Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest 2009; 119(8):2388-98.
120. Martino AT, Suzuki M, Markusic DM, et al. The genome of selfcomplementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 2011; 117(24):6459-68.
121. Faust SM, Bell P, Cutler BJ, et al. CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Invest 2013; 123(7):2994-3001.
122. Yan Z, Zhang Y, Duan D, Engelhardt JF. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci U S A 2000; 97(12):6716-21.
123. Lai Y, Yue Y, Liu M, et al. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol 2005; 23(11):1435-9.
124. Wang L, Rosenberg JB, De BP, et al. In vivo gene transfer strategies to achieve partial correction of von Willebrand disease. Hum Gene Ther 2012; 23(6):576-88.
125. Schenk-Braat EA, van Mierlo MM, Wagemaker G, Bangma CH, Kaptein LC. An inventory of shedding data from clinical gene therapy trials. J Gene Med 2007; 9(10):910-21.
126. Wagner JA, Reynolds T, Moran ML, et al. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet 1998; 351(9117):1702-3.
127. Le Guiner C, Moullier P, Arruda VR. Biodistribution and shedding of AAV vectors. Methods Mol Biol 2011; 807:339-59.
128. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008; 358 (21):2231-9.
129. Brantly ML, Chulay JD, Wang L, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A 2009; 106(38):16363-8.
130. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008; 358(21):2240-8.
131. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003;101 (8):2963-72.
132. Favaro P, Finn JD, Siner JI, Wright JF, High KA, Arruda VR. Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal model. Hum Gene Ther 2011; 22(7):843-52.
133. Brandon EF, Hermsen HP, van Eijkeren JC, Tiesjema B. Effect of administration route on the biodistribution and shedding of replication-deficient AAV2: a qualitative modelling approach. Curr Gene Ther 2010; 10(2):91-106.
134. Tenenbaum L, Lehtonen E, Monahan PE. Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther 2003; 3(6):545-65.
135. Afione SA, Conrad CK, Kearns WG, et al. In vivo model of adenoassociated virus vector persistence and rescue. J Virol 1996; 70(5):3235-41.
136. Hewitt FC, Li C, Gray SJ, Cockrell S, Washburn M, Samulski RJ. Reducing the risk of adeno-associated virus (AAV) vector mobilization with AAV type 5 vectors. J Virol 2009; 83(8):3919-29.
137. Honaramooz A, Megee S, Zeng W, et al. Adeno-associated virus (AAV)-mediated transduction of male germ line stem cells results in transgene transmission after germ cell transplantation. FASEB J 2008; 22(2):374-82.
138. Zeng W, Tang L, Bondareva A, et al. Viral transduction of male germline stem cells results in transgene transmission after germ cell transplantation in pigs. Biol Reprod 2013;88(1):27.
139. Patterson AP, Mickelson CA. U.S. Department of Health and Human Services National Institutes of Health Recombinant DNA Advisory Committee. Minutes of Meeting, December 6, 2001. Hum Gene Ther 2002; 13(13):1663-73.
140. Arruda VR, Fields PA, Milner R, et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol Ther 2001; 4(6):586-92.
141. Favre D, Provost N, Blouin V, et al. Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. Mol Ther 2001; 4(6):559-66.
142. Song S, Scott-Jorgensen M, Wang J, et al. Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects. Mol Ther 2002; 6(3):329-35.
143. Toromanoff A, Cherel Y, Guilbaud M, et al. Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther 2008; 16(7):1291-9.
144. Schuettrumpf J, Liu JH, Couto LB, et al. Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial. Mol Ther 2006; 13(6):1064-73.
145. Favaro P, Downey HD, Zhou JS, et al. Host and vector-dependent effects on the risk of germline transmission of AAV vectors. Mol Ther 2009; 17(6):1022-30.
146. Kube DM, Ponnazhagan S, Srivastava A. Encapsidation of adenoassociated virus type 2 Rep proteins in wild-type and recombinant progeny virions: Rep-mediated growth inhibition of primary human cells. J Virol 1997; 71(10):7361-71.
147. Wang XS, Srivastava A. Rescue and autonomous replication of adeno-associated virus type 2 genomes containing Rep-binding site mutations in the viral p5 promoter. J Virol 1998; 72(6):4811-8.
148. Wang XS, Khuntirat B, Qing K, et al. Characterization of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their elimination. J Virol 1998; 72(7):5472-80.
149. Allen JM, Debelak DJ, Reynolds TC, Miller AD. Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production. J Virol 1997; 71(9):6816-22.
150. Cao L, Liu Y, During MJ, Xiao W. High-titer, wild-type free recombinant adeno-associated virus vector production using introncontaining helper plasmids. J Virol 2000; 74(24):11456-63.
151. Halbert CL, Metzger MJ, Lam SL, Miller AD. Capsid-expressing DNA in AAV vectors and its elimination by use of an oversize capsid gene for vector production. Gene Ther 2011; 18(4):411-7.
152. Dong B, Moore AR, Dai J, et al. A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy. Nucleic Acids Res 2013; 41(13):6609-17.
153. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302(5644):415-9.
154. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassemia. Nature 2010; 467 (7313):318-22.
155. Nakai H, Iwaki Y, Kay MA, Couto LB. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J Virol 1999; 73(7):5438-47.
156. Miller DG, Rutledge EA, Russell DW. Chromosomal effects of adeno-associated virus vector integration. Nat Genet 2002; 30(2):147-8.
157. Nowrouzi A, Penaud-Budloo M, Kaeppel C, et al. Integration frequency and intermolecular recombination of rAAV vectors in non-human primate skeletal muscle and liver. Mol Ther 2012; 20(6):1177-86.
158. Inagaki K, Lewis SM, Wu X, et al. DNA palindromes with a modest arm length of greater, similar 20 base pairs are a significant target for recombinant adeno-associated virus vector integration in the liver, muscles, and heart in mice. J Virol 2007; 81(20):11290-303.
159. Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007; 317(5837):477.
160. Donsante A, Vogler C, Muzyczka N, et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 2001; 8(17):1343-6.
161. Janovitz T, Klein IA, Oliveira T, et al. High-throughput sequencing reveals principles of adeno-associated virus serotype 2 integration. J Virol 2013; 87(15):8559-68.
162. Rosas LE, Grieves JL, Zaraspe K, La Perle KM, Fu H, McCarty DM. Patterns of scAAV vector insertion associated with oncogenic events in a mouse model for genotoxicity. Mol Ther 2012; 20(11):2098-110.
163. Nakai H, Fuess S, Storm TA, Meuse LA, Kay MA. Free DNA ends are essential for concatemerization of synthetic double-stranded adeno-associated virus vector genomes transfected into mouse hepatocytes in vivo. Mol Ther 2003; 7(1):112-21.
164. Nakai H, Wu X, Fuess S, et al. Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol 2005; 79(6):3606-14.
165. Li H, Malani N, Hamilton SR, et al. Assessing the potential for AAV vector genotoxicity in a murine model. Blood 2011; 117(12):3311-9.
166. Paneda MA, Lopez-Franco E, Kaeppel C, et al. Safety and liver transduction efficacy of rAAV5-cohPBGD in non-human primates: A potential therapy for Acute Intermitent Porphyria. Hum Gene Ther 2013; 24(12):1007-17.
167. Kaeppel C, Beattie SG, Fronza R, et al. A largely random AAV integration profile after LPLD gene therapy. Nat Med 2013; 19(7):889-91.
168. Bell P, Moscioni AD, McCarter RJ, et al. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther 2006; 14(1):34-44.
169. Bell P, Wang L, Lebherz C, et al. No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol Ther 2005; 12(2):299-306.
170. Gauttier V, Pichard V, Aubert D, et al. No tumour-initiating risk associated with scAAV transduction in newborn rat liver. Gene Ther 2013; 20(7):779-84.
171. Goncalves MA, van der Velde I, Knaan-Shanzer S, Valerio D, de Vries AA. Stable transduction of large DNA by high-capacity adeno-associated virus/adenovirus hybrid vectors. Virology 2004; 321(2):287-96.
172. Recchia A, Parks RJ, Lamartina S, et al. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc Natl Acad Sci U S A 1999; 96(6):2615-20.
173. Vandenberghe LH, Wilson JM, Gao G. Tailoring the AAV vector capsid for gene therapy. Gene Ther 2009; 16(3):311-9.
174. Pacak CA, Sakai Y, Thattaliyath BD, Mah CS, Byrne BJ. Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice. Genet Vaccines Ther 2008; 6:13.
175. Sun X, Pawlyk B, Xu X, et al. Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations. Gene Ther 2010; 17(1):117-31.
176. Brown BD, Venneri MA, Zingale A, Sergi Sergi L, Naldini L. Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 2006; 12(5):585-91.
177. Karali M, Manfredi A, Puppo A, et al. MicroRNA-restricted transgene expression in the retina. PLoS One 2011; 6(7):e22166.
178. Xie J, Xie Q, Zhang H, et al. MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Mol Ther 2011; 19(3):526-35.
179. Qiao C, Yuan Z, Li J, et al. Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Gene Ther 2011; 18(4):403-10.
180. Ardiani A, Johnson AJ, Ruan H, Sanchez-Bonilla M, Serve K, Black ME. Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy. Curr Gene Ther 2012; 12(2):77-91.
181. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 1992; 89(12):5547-51.
182. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268(5218):1766-9.
183. Hadaczek P, Beyer J, Kells A, et al. Evaluation of an AAV2-based rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system. PLoS One 2011; 6(11):e27728.
184. Rivera VM, Clackson T, Natesan S, et al. A humanized system for pharmacologic control of gene expression. Nat Med 1996; 2(9):1028-32.
185. Maddalena A, Tereshchenko J, Bahr M, Kugler S. Adenoassociated Virus-mediated, Mifepristone-regulated Transgene Expression in the Brain. Mol Ther Nucleic Acids 2013; 2:e106.
186. Roscilli G, Rinaudo CD, Cimino M, et al. Long-term and tight control of gene expression in mouse skeletal muscle by a new hybrid human transcription factor. Mol Ther 2002; 6(5):653-63.
187. Banaszynski LA, Chen LC, Maynard-Smith LA, Ooi AG, Wandless TJ. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 2006; 126(5):995-1004.
188. Quintino L, Manfre G, Wettergren EE, Namislo A, Isaksson C, Lundberg C. Functional Neuroprotection and Efficient Regulation of GDNF Using Destabilizing Domains in a Rodent Model of Parkinson's Disease. Mol Ther 2013; 21(12):2169-80.
189. Antoniou T, Gomes T, Mamdani MM, Juurlink DN. Trimethoprim/ sulfamethoxazole-induced phenytoin toxicity in the elderly: a population-based study. Br J Clin Pharmacol 2011; 71(4):544-9.
190. Burgos MI, Fernandez RA, Celej MS, Rossi LI, Fidelio GD, Dassie SA. Binding of the highly toxic tetracycline derivative, anhydrotetracycline, to bovine serum albumin. Biol Pharm Bull 2011; 34(8):1301-6.
191. Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: a pleiotropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010; 299(3):C539-48.
192. Blasey CM, Block TS, Belanoff JK, Roe RL. Efficacy and safety of mifepristone for the treatment of psychotic depression. J Clin Psychopharmacol 2011; 31(4):436-40.
193. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65(2):232-60.
194. Wright GD. Antibiotics: inactive but not inert. Nat Chem Biol 2010; 6(2):85-6.
195. Manfredsson FP, Burger C, Rising AC, et al. Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther 2009; 17(11):1857-67.
196. Manfredsson FP, Okun MS, Mandel RJ. Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease. Curr Gene Ther 2009; 9(5):375-88.
197. Manfredsson FP, Bloom DC, Mandel RJ. Regulated protein expression for in vivo gene therapy for neurological disorders: progress, strategies, and issues. Neurobiol Dis 2012; 48(2):212-21.
198. Yang X, Mertens B, Lehtonen E, et al. Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model. J Gene Med 2009; 11(10):899-912.
199. Zhou X, Vink M, Klaver B, Berkhout B, Das AT. Optimization of the Tet-On system for regulated gene expression through viral evolution. Gene Ther 2006; 13(19):1382-90.
200. Henssler EM, Scholz O, Lochner S, Gmeiner P, Hillen W. Structure-based design of Tet repressor to optimize a new inducer specificity. Biochemistry 2004; 43(29):9512-8.
201. Das AT, Zhou X, Vink M, et al. Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J Biol Chem 2004; 279(18):18776-82.
202. Ginhoux F, Turbant S, Gross DA, et al. HLA-A*0201-restricted cytolytic responses to the rtTA transactivator dominant and cryptic epitopes compromise transgene expression induced by the tetracycline on system. Mol Ther 2004; 10(2):279-89.
203. Favre D, Blouin V, Provost N, et al. Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adenoassociated virus. J Virol 2002; 76(22):11605-11.
204. Stieger K, Le Meur G, Lasne F, et al. Long-term doxycyclineregulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Mol Ther 2006; 13(5):967-975.
205. Xiong W, Candolfi M, Kroeger KM, et al. Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain. Mol Ther 2008; 16(2):343-51.
206. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006; 296(8):964-73.
207. Burcin MM, Schiedner G, Kochanek S, Tsai SY, O'Malley BW. Adenovirus-mediated regulable target gene expression in vivo. Proc Natl Acad Sci U S A 1999; 96(2):355-60.
208. Bockstael O, Chtarto A, Wakkinen J, et al. Differential transgene expression profiles in rat brain, using rAAV2/1 vectors with tetracycline-inducible and cytomegalovirus promoters. Hum Gene Ther 2008; 19(11):1293-305.
209. Rayaprolu V, Kruse S, Kant R, et al. Comparative Analysis of Adeno Associated Virus Capsid Stability and Dynamics. J Virol 2013; doi:10.1128/JVI.01415-13.
210. Croyle MA, Cheng X, Wilson JM. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther 2001; 8(17):1281-90.
211. Monahan PE, Rabinowitz JE, Samulski RJ. Stability of recombinant adeno-associated virus vectors permits delivery on implantable matrices. Blood 2000; 96(11):525a-Abstract #2256.
212. Center for Disease Control and Prevention. Emergency Needlestick Information. Available at: http://www.cdc.gov/niosh/topics/bbp/ emergnedl.html, 2013.
213. Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking, and opportunities for mutation-specific treatment. Chest 2011; 139(6):1480-90.
214. Conrad CK, Allen SS, Afione SA, et al. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther 1996; 3(8):658-68.
215. EMEA. General principles to address virus and vector shedding. ICH Considerations. ICH 2009;EMEA/CHMP/ICH/449035/2009.
216. Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy of cystic fibrosis. Methods Enzymol 1998; 292:717-32.
217. Wagner JA, Messner AH, Moran ML, et al. Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 1999; 109(2 Pt 1):266-74.
218. Zabner J, Seiler M, Walters R, et al. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000; 74(8):3852-8.
219. Brantly ML, Spencer LT, Humphries M, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006; 17(12):1177-86.
220. Flotte TR, Trapnell BC, Humphries M, et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther 2011; 22(10):1239-47.
221. Christine CW, Starr PA, Larson PS, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009; 73 (20):1662-9.
222. Mandel RJ. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther 2010; 12(2):240-7.
223. Dodge JC, Haidet AM, Yang W, et al. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol Ther 2008; 16(6):1056-64.
224. Worgall S, Sondhi D, Hackett NR, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 2008; 19(5):463-74.
225. Duque S, Joussemet B, Riviere C, et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 2009; 17(7):1187-96.
226. Gray SJ, Matagne V, Bachaboina L, Yadav S, Ojeda SR, Samulski RJ. Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 2011 Jun;19(6):1058-1069.
227. McPhee SW, Janson CG, Li C, Samulski RJ, Camp AS, Francis J, et al. Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 2006 May;8(5):577-588.
228. Leone P, Shera D, McPhee SWJ, et al. Long-Term Follow-Up after Gene Therapy for Canavan Disease. Science Translational Medicine 2012; 4(165):165ra163.
229. Carlsson A. A half-century of neurotransmitter research: impact on neurology and psychiatry. Nobel lecture. Biosci Rep 2001; 21(6):691-710.
230. Mandel RJ, Rendahl KG, Snyder RO, Leff SE. Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson's disease using recombinant adeno-associated viral vectors. Exp Neurol 1999; 159(1):47-64.
231. Eberling JL, Jagust WJ, Christine CW, et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008; 70(21):1980-3.
232. Mittermeyer G, Christine CW, Rosenbluth KH, et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther 2012; 23(4):377-81.
233. Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007; 369(9579):2097-105.
234. LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011; 10(4):309-19.
235. Marks WJ, Jr, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010; 9(12):1164-72.
236. Bartus RT, Herzog CD, Chu Y, et al. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord 2011; 26(1):27-36.
237. Georgievska B, Kirik D, Bjorklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 2002; 177(2):461-74.
238. Hovland DN Jr, Boyd RB, Butt MT, et al. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF in rhesus monkeys. Toxicol Pathol 2007; 35(7):1013-29.
239. Manfredsson FP, Tumer N, Erdos B, et al. Nigrostriatal rAAVmediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther 2009; 17(6):980-91.
240. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, doubleblind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003; 60(1):69-73.
241. Cressant A, Desmaris N, Verot L, et al. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J Neurosci 2004; 24(45):10229-39.
242. Journal of Gene Medicine. http://www.abedia.com/wiley/record_ detail.php?ID=341.
243. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector J Virol 1996; 70(11):8098-108.
244. Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne's muscular dystrophy N Engl J Med 2010; 363(15):1429-37.
245. Qiao C, Li J, Zheng H, et al. Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth. Hum Gene Ther 2009; 20(1):1-10.
246. Toromanoff A, Adjali O, Larcher T, et al. Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. Mol Ther 2010; 18(1):151-60.
247. Sun B, Li S, Bird A, Koeberl DD. Hydrostatic isolated limb perfusion with adeno-associated virus vectors enhances correction of skeletal muscle in Pompe disease. Gene Ther 2010; 17(12):1500-5.
248. Acland GM, Aguirre GD, Bennett J, et al. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 2005; 12(6):1072-82.
249. Ali R. Gene transfer into the mouse retina mediated by an adenoassociated viral vector. Hum Mol Genet 1996; 5(5):591-4.
250. Cremers FPM. Molecular genetics of Leber congenital amaurosis. Hum Mol Genet 2002; 11(10):1169-76.
251. Hanein S, Perrault I, Gerber S, et al. Leber congenital amaurosis: comprehensive survey of the genetic heterogeneity, refinement of the clinical definition, and genotype-phenotype correlations as a strategy for molecular diagnosis. Hum Mutat 2004; 23(4):306-17.
252. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28(1):92-5.
253. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008; 19(10):979-90.
254. Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 2010; 18(3):643-50.
255. Banin E, Bandah-Rozenfeld D, Obolensky A, et al. Molecular Anthropology Meets Genetic Medicine to Treat Blindness in the North African Jewish Population: Human Gene Therapy Initiated in Israel. Hum Gene Ther 2010; 21(12):1749-57.
256. Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Science Translational Medicine 2012; 4(120):120ra15.
257. Campochiaro PA. Gene transfer for neovascular age-related macular degeneration. Hum Gene Ther 2011; 22(5):523-9.
258. Maclachlan TK, Lukason M, Collins M, Munger R, Isenberger E, Rogers C, et al. Preclinical safety evaluation of AAV2-sFLT01-a gene therapy for age-related macular degeneration. Mol Ther 2011; 19(2):326-34.
259. Lai CM, Estcourt MJ, Himbeck RP, et al. Preclinical safety evaluation of subretinal AAV2. sFlt-1 in non-human primates. Gene Ther 2012; 19(10):999-1009.
260. Rakoczy EP, Lai MC, Pierce C, et al. Gene Therapy for Wet-AMD: Progress Report on a Phase I/II Clinical Trial. American Society of Gene and Cell Therapy, 16th Annual Meeting; 2013, Abstract 54.
261. Vandenberghe LH, Auricchio A. Novel adeno-associated viral vectors for retinal gene therapy. Gene Ther 2012; 19(2):162-8.
262. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24(3):257-61.
263. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101(8):2963-72.
264. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12(3):342-7.
265. Mingozzi F, Maus MV, Hui DJ, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007; 13(4):419-22.
266. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther 2007; 7(5):316-24.
267. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365(25):2357-65.
268. Vandenberghe LH, Wang L, Somanathan S, et al. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Nat Med 2006; 12(8):967-71.
269. Carpentier AC, Frisch F, Labbe SM, et al. Effect of alipogene tiparvovec (AAV1-LPL(S447X) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab 2012; 97(5):1635-44.
270. Nierman MC, Rip J, Kuivenhoven JA, et al. Carriers of the frequent lipoprotein lipase S447X variant exhibit enhanced postprandial apoprotein B-48 clearance. Metabolism 2005; 54(11):1499-503.
271. Stroes ES, Nierman MC, Meulenberg JJ, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 2008; 28(12):2303-4.
272. Mingozzi F, Meulenberg JJ, Hui DJ, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 2009; 114(10):2077-86.
273. Gaudet D, Methot J, Dery S, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 2013; 20(4):361-9.
274. Moran N. First gene therapy nears landmark European market authorization. Nat Biotechnol 2012; 30(9):807-9.
275. Bryant LM, Christopher DM, Giles AR, et al. Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev 2013; 24(2):55-64.
276. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 2013; 122(1):23-36.
277. Wang Z, Tapscott SJ, Chamberlain JS, Storb R. Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials. Front Microbiol 2011; 2:201.
278. Mays LE, Wilson JM. The Complex and Evolving Story of T cell Activation to AAV Vector-encoded Transgene Products. Mol Ther 2011 01-04; 19(1):16-27.
279. Crile GW editor. Crile GW: Hemorrhage and Transfusion: An Experimental and Clinical Research. New York: D. Appleton; 1909.
280. Willett K, Bennett J. Immunology of AAV-Mediated Gene Transfer in the Eye. Front Immunol 2013; 4:261.
281. Jenal U, Salmon F. Environmental Risk Assessment for the placing of the market of the gene therapy product Glybera. European Society of Gene and Cell Therapy and Sociedad Espanola de Terapie Genica y Celular Collaborative Congress 2013; 2013, Abstract OE023.
282. Foust KD, Salazar DL, Likhite S, Ferraiuolo L, Ditsworth D, Ilieva H, Meyer K, Schmelzer L, Braun L, Cleveland DW, Kaspar BK. Therapeutic AAV9-mediated Suppression of Mutant SOD1 Slows Disease Progression and Extends Survival in Models of Inherited ALS. Mol Ther. 2013; 21:2148-59.
283. McCown TJ. The future of epilepsy treatment: focus on adenoassociated virus vector gene therapy. Drug News Perspect. 2010; 23:281-6.